foxo4-dri human trial senolytic The disordered p53 transactivation domain is the target of FOXO4 and the compound FOXO4-DRI Peptide Dosing Guide: Senolytic
Description
Unick, J
Improving vascular health
results will establish CV safety/benefit profile Interim Data (SURPASS-4): Earlier trial showed 26% reduction in 3-point MACE vs
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication
